Kuraray and CellRev Partner to support optimised cell culture systems in Regenerative Medicine

The Kuraray Life Innovation Business Promotion Department, a division of Kuraray Co., Ltd. (TYO: 3406), a global leader in specialty chemicals, and Cellularevolution Ltd. (CellRev), an innovative developer of bioprocessing media additives, have entered into a strategic partnership aimed at enhancing cell culture solutions within the mesenchymal stem cells (MSCs) market segment.

This partnership will initiate with a commercial pilot running from June to November 2025 with a focus on the Japanese market. The collaboration will feature a novel trial kit, combining Kuraray’s SCAPOVA™ microcarrier beads, CellRev's breakthrough AggreGuard™ media additive, and a technical protocol to support customer success. AggreGuard™ uniquely increases cell viability, thus significantly improving productivity and consistency in cell culture processes – overall reducing the complexity in bioprocess development.

The joint trial kit aims to support researchers and companies within regenerative medicine, specifically targeting the fast-growing MSC market—valued at approximately USD 3.12 billion in 2023 and expected to reach USD 7.27 billion by 2030.

Chris Green, CEO of CellRev, stated, "It's tremendous to see this partnership come to life. Kuraray Life Innovation Business Promotion Department have an excellent understanding of our technology. They possess the perfect mix of scientific and commercial skills to support MSC-derived therapeutic developers in improving their production processes."

Through coordinated marketing initiatives, including cross-promotional content, shared application notes, and joint technical support, Kuraray and CellRev are committed to providing exceptional customer experiences. Kuraray will lead sales and distribution efforts for the trial kits in Japan, while CellRev will offer specialised technical support and assistance with prospective customers.

"This partnership represents a significant step forward in the pursuit of optimised lower cost manufacturing for regenerative medicine innovators," said representatives from both companies. "By combining Kuraray’s excellence in materials science and CellRev's pioneering bioprocessing additives, we aim to set new standards in cell culture efficacy and scalability."

Both Kuraray and CellRev anticipate this strategic collaboration to expand their market reach and enhance brand awareness, positioning SCAPOVA™ and AggreGuard™ as preferred choices within the regenerative medicine community. 

For further information, please contact: Chris Green, CEO E-mail: enquiry@cellrev.co.uk